🇺🇸 ARWR — Arrowhead Pharmaceuticals, Inc.

Salud Compra fuerte
← Volver

Precio actual

61,65 USD

Máx. histórico

2.925,00

12011 días

Split 1:10 del 17/11/2011

Caída desde máximo

-97,89%

Rango 52 semanas

37,06 – 95,49

Variación hoy

+3,56%

Cierre anterior

59,53

Rango de hoy

59,06 – 61,99

Volumen hoy

1.487.357

Peor caída histórica

-99,96%

16/12/1993 → 16/12/2016

Aún sin recuperar

Volatilidad anualizada ⓘ

231,86%

Información
Nombre completo
Arrowhead Pharmaceuticals, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
711
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
107,71 USD (puede no estar actualizado)
Primera cotización
16/12/1993
Precio actualizado
hace 9 horas
Sobre la empresa

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.

Splits Registrados en el histórico de precios
Fecha Ratio
17/11/2011 1:10
15/01/2004 1:65
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/03/2017 2,16 2,18 2,08 2,10 -3,67% 4,63% 585.900
06/03/2017 2,20 2,25 2,14 2,18 -1,80% 5,00% 430.900
03/03/2017 2,25 2,30 2,20 2,22 -1,33% 4,44% 390.500
02/03/2017 2,37 2,42 2,24 2,25 -3,43% 7,59% 858.000
01/03/2017 2,28 2,34 2,22 2,33 +3,10% 5,26% 726.500
28/02/2017 2,40 2,40 2,25 2,26 -4,24% 6,25% 956.100
27/02/2017 2,16 2,45 2,15 2,36 +9,77% 13,89% 2.695.500
24/02/2017 2,11 2,16 2,08 2,15 +1,42% 3,79% 423.700
23/02/2017 2,14 2,16 2,09 2,12 -0,93% 3,08% 470.100
22/02/2017 2,16 2,18 2,08 2,14 -0,47% 4,63% 841.100
21/02/2017 2,20 2,21 2,12 2,15 -0,92% 4,09% 569.200
17/02/2017 2,22 2,22 2,11 2,17 -0,91% 4,95% 904.600
16/02/2017 2,15 2,23 2,07 2,19 +3,30% 7,44% 2.110.500
15/02/2017 1,99 2,14 1,96 2,12 +5,47% 9,05% 1.703.500
14/02/2017 1,94 2,03 1,90 2,01 +4,15% 6,70% 687.600
13/02/2017 2,00 2,01 1,92 1,93 -2,03% 4,50% 535.900
10/02/2017 2,10 2,10 1,94 1,97 -3,90% 7,62% 645.500
09/02/2017 2,02 2,10 2,01 2,05 +1,49% 4,46% 740.600
08/02/2017 1,99 2,12 1,91 2,02 +3,06% 10,45% 1.375.000
07/02/2017 1,93 2,15 1,80 1,96 +4,26% 18,13% 2.314.400
06/02/2017 1,94 1,97 1,83 1,88 -1,05% 7,22% 578.700
03/02/2017 1,84 1,93 1,77 1,90 +4,40% 8,70% 837.000
02/02/2017 1,75 1,83 1,75 1,82 +4,60% 4,57% 668.400
01/02/2017 1,96 2,08 1,71 1,74 -10,31% 18,88% 1.984.800
31/01/2017 1,77 1,97 1,70 1,94 +10,86% 14,97% 1.089.800
30/01/2017 1,78 1,80 1,70 1,75 -1,69% 5,62% 449.100
27/01/2017 1,80 1,80 1,71 1,78 +1,14% 5,00% 497.500
26/01/2017 1,82 1,85 1,76 1,76 -3,83% 4,95% 538.700
25/01/2017 1,75 1,84 1,74 1,83 +4,57% 5,71% 680.800
24/01/2017 1,73 1,75 1,70 1,75 +1,16% 2,89% 555.600